Antenatal Exposure to Magnesium Sulfate and Neuroprotection in Preterm Infants

Costantine, Maged M.; Drever, Nathan

doi:10.1016/j.ogc.2011.02.019

Cited by 31 publications

(24 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Se desconoce el régimen antenatal óptimo de sulfato de magnesio para la neuroprotección fetal en cuanto a dosis y duración: aún se permite repetir las dosis y el tiempo (50). Se encontró asociación entre el sulfato de magnesio y la disminución del riesgo de parálisis cerebral cuando se utilizaba para tocólisis y preeclampsia, lo cual podría guiar el régimen de elección.…”

Section: Sulfato De Magnesiounclassified

Guía fármacoterapeutica de amenaza de parto pretérmino

Osorio

Garcia

2015

Rev. Colomb. Enferm.

View full text Add to dashboard Cite

RESUMENEl parto pretérmino representa un reto terapéutico ya que su tratamiento oportuno disminuye la morbilidad y mortalidad neonatal. Afecta de 5 a 11% de todos los partos en el mundo, entre 9 y 10% en países de bajos ingresos y de 6 a 11,9% en países con altos ingresos. Es el responsable de 70% de las muertes neonatales y 37% de las muertes en infantes así como el causante de 25 a 50% de los casos de falla en el desarrollo neurológico en niños. Por lo anterior, es importante realizar un adecuado tamizaje y tratamiento de las pacientes que se encuentran en riesgo de parto pretérmino. Para ello, se realizó una guía fármacoterapeutica basada en la mejor evidencia para su manejo.Palabras clave: parto pretérmino, magnesio, esteroides, progesterona, tocólisis. Artículo de RevisiónGuía fármacoterapeutica de amenaza de parto pretérmino ABSTRACT preterm labor represents a therapeutic challenge because opportune treatment decreases neonatal morbidity and mortality. It affects 5-11% of all worldwide births. Of these births 9-10% occurred in low-income countries and 6-11.9% in high-income countries. Preterm labor is responsible for 70% of neonatal deaths and 37% of infant deaths; it causes 25-50% of the cases of neurological development failure in children. Because of this, it is important to perform adequate screening and treatment of patients at risk for preterm delivery. A pharmaceutical guide based on the best evidence for its management was performed.Key words: premature birth, magnesium, steroids, progesterone, tocolysis. RESUMOO parto prematuro representa um desafio terapêutico, uma vez que seu tratamento oportuno diminui a morbidez e mortalidade neonatal. Afeta de 5 a 11% de todos os partos no mundo, sendo que, entre 9 e 10% ocorrem em países de baixa renda, e de 6 a 11,9%, em países de alta renda. É responsável por 70% das mortes neonatais e 37% das mortes em recém-nascidos, assim como é o causador de 25 a 50% dos casos de falha no desenvolvimento neurológico em crianças. Por este motivo, é importante realizar uma triagem e tratamento adequados das pacientes que se encontram em risco de parto prematuro. Portanto, foi elaborado um guia farmacoterapêutico com base na melhor evidência para seu manuseio.Palavras-chave: parto prematuro, magnésio, esteroides, progesterona, tocólise.

show abstract

Section: Sulfato De Magnesiounclassified

Guía fármacoterapeutica de amenaza de parto pretérmino

Osorio

Garcia

2015

Rev. Colomb. Enferm.

View full text Add to dashboard Cite

show abstract

“…Previous reports suggested that MgSO 4 administration prevented the effects of energy depletion after an HI event in newborn children trials [116] and altered important enzymes in erythrocyte membrane from asphyxiated newborns, reducing the postasphyxial damage [117]. However, other multicenter trials have pointed out on the one hand the absence of a therapeutic effect [118,119] and on the other hand, magnesium administration has even been considered to be harmful for the fetus [120,121], although this opinion is not unanimously held [122,123,124] and the question is still unclear. These paradoxical perspectives regarding the neuroprotective effect of MgSO 4 administration could be the consequence of the variability in the study design, depending on the dose and the experimental model, making it difficult to compare the outcomes directly.…”

Section: Pharmacological Therapiesmentioning

confidence: 99%

Neuroprotective Therapies after Perinatal Hypoxic-Ischemic Brain Injury

et al. 2013

View full text Add to dashboard Cite

Hypoxic-ischemic (HI) brain injury is one of the main causes of disabilities in term-born infants. It is the result of a deprivation of oxygen and glucose in the neural tissue. As one of the most important causes of brain damage in the newborn period, the neonatal HI event is a devastating condition that can lead to long-term neurological deficits or even death. The pattern of this injury occurs in two phases, the first one is a primary energy failure related to the HI event and the second phase is an energy failure that takes place some hours later. Injuries that occur in response to these events are often manifested as severe cognitive and motor disturbances over time. Due to difficulties regarding the early diagnosis and treatment of HI injury, there is an increasing need to find effective therapies as new opportunities for the reduction of brain damage and its long term effects. Some of these therapies are focused on prevention of the production of reactive oxygen species, anti-inflammatory effects, anti-apoptotic interventions and in a later stage, the stimulation of neurotrophic properties in the neonatal brain which could be targeted to promote neuronal and oligodendrocyte regeneration.

show abstract

“…1 The International Executive Committee for the Definition o f C e r e b r a l P a l s y p r o p o s e d t h e following definition: "A group of lifelong disorders of the development of movement and posture, causing activity limitations that are attributed to non-progressive disturbances that occurred in the developing fetal or infant brain. Motor disorders of cerebral palsy are often accompanied b y d i s t u r b a n c e s o f s e n s a t i o n , perception, cognition, communication and behavior, by epilepsy and b y s e c o n d a r y m u s c u l o s k e l e t a l problems."…”

Section: Introductionmentioning

confidence: 99%

“…Motor disorders of cerebral palsy are often accompanied b y d i s t u r b a n c e s o f s e n s a t i o n , perception, cognition, communication and behavior, by epilepsy and b y s e c o n d a r y m u s c u l o s k e l e t a l problems." 2 The prevalence of cerebral palsy is approximately 2-4/1000 live births 1,3 and its main risk factors include prematurity and multiple pregnancy. The incidence of prematurity is increasing; for example in the United States, it increased 36% between 1981 and 2008, and in Denmark it rose 22% between 1995 and 2004.…”

Section: Introductionmentioning

confidence: 99%

Update on the use of magnesium sulphate for fetal neuroprotection in preterm birth.

2015

Arch Argent Pediat

View full text Add to dashboard Cite

The administration of magnesium sulphate to mothers at risk for preterm birth for fetal neuroprotection has demonstrated to reduce the risk of cerebral palsy and gross motor dysfunction by 30-40%. Although there is controversy regarding the regimen of administration of magnesium sulphate, the gestational age limit, the extent of its potential benefit or even if it provides any benefit, current evidence is enough to support the use of magnesium sulphate in women at imminent risk for preterm delivery before 32 weeks of gestation. The objective of this study is to describe available evidence and current recommendations regarding neuroprotection with magnesium sulphate.

show abstract

Antenatal Exposure to Magnesium Sulfate and Neuroprotection in Preterm Infants

Cited by 31 publications

References 49 publications

Guía fármacoterapeutica de amenaza de parto pretérmino

Guía fármacoterapeutica de amenaza de parto pretérmino

Neuroprotective Therapies after Perinatal Hypoxic-Ischemic Brain Injury

Update on the use of magnesium sulphate for fetal neuroprotection in preterm birth.

Contact Info

Product

Resources

About